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Introduction
Obtaining protein profiles from a pure cell population can significantly improve our capability in protein biomarker discovery. Laser capture microdissection (LCM) is an important tool for acquisition of specific cells of interest from heterogeneous tissue sections(1, 2). Obtaining protein profiles from laser microdissected cells has been explored using multidimensional liquid chromatography -mass spectrometry or gel electrophoresis (3) (4) (5) . However, usually approximately 30,000 cells are required for these approaches (6) (7) (8) . Direct analysis of laser microdissected cells using matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) is a sensitive, accurate, and high-throughput technique to obtain protein profiles from limited numbers of cells (~100 cells) (9) (10) (11) . Combining LCM and MALDI MS is a promising tool for discovery of protein biomarkers from minute tissue structures.
Individuals with advanced colorectal cancer (CRC) continue to have a poor prognosis despite recent improvements in treatment. As a result, early diagnosis and improved understanding of the pathogenesis of CRC are vital for improved clinical outcomes. Identification of early CRC protein markers has the potential to result in earlier diagnosis, more accurate prognosis, and improved treatment for individuals with CRC.
Colorectal neoplasia is believed to arise from the colonic crypt (12, 13) . The colon is a self-renewing epithelium that consists of an actively dividing, relatively undifferentiated crypt base and a non-dividing, differentiated surface compartment (14) (15) (16) Adenomatous polyps originate from crypts and represent important precursor lesions in the adenomacarcinoma sequence (12) . The Apc Min+/-mouse model, and other similar models based on truncating mutations in Apc, have been widely used to study intestinal neoplasia. This model contains a germline mutation in the adenomatous polyposis coli (APC) gene (17) , leading to numerous adenomas in the intestine (18) . In humans, loss of APC is often an early event in the cascade of genetic mutations that lead to colorectal neoplasia (19) .
Approximately 80% of all sporadic human CRC have inactivating mutations in the APC gene (20) . Similarly, human familial adenomatous polyposis (FAP) patients have germline mutations in the APC gene, and loss of heterozygosity leads to the development of hundreds of adenomatous polyps in colon and rectum. Thus, the Apc Min+/-mouse is a promising mouse model for the discovery of potential early CRC markers using a proteomic approach.
As a discovery study, we aimed to identify a set of proteomic profiles that can differentiate murine top and bottom crypt and Apc Min+/-adenomas using LCM combined with MALDI MS. Specific protein biomarkers would be identified using tandem mass spectrometry. Finally, the relevance of the identified protein biomarkers would be examined in human CRC at both protein and mRNA levels.
Experimental Procedures

Laser Capture Microdissection and MALDI Mass Spectrometry
Four distal colons were obtained from wild-type mice. Seven small intestinal adenomas and one large intestinal adenoma were obtained from eight Apc Min+/-adult mice. The mice were in C57/BL6 background. The tissues were fresh frozen and five micron sections were obtained from the samples using a cryostat. The tissue sections were dehydrated as previously described (9) . Hematoxylin and Eosin stained sections were also prepared for visual reference. The LCM was performed using an Arcturus PixCell II LCM system and 
Acoustic Matrix Solution Deposition
For human CRC analysis, 66 controls and 104 CRC cases were obtained retrospectively through the Vanderbilt Human Tissue Resource. The frozen samples were cut to 12 μm sections and mounted on a MALDI target plate. After a brief dehydration process (in 70% ethanol 60 seconds, 100% ethanol 15 seconds, and dry in vacuum 5 minutes), sinapinic acid matrix solution was deposited onto the tissue sections at specific cells of interest using an acoustic matrix spotter (21) . Approximately 200 μm matrix spots were formed at the crypt epithelial cell regions for control samples and tumor cells for CRC samples. MALDI mass spectra were obtained from each case using the mass spectrometer described previously. Each mass spectrum was obtained averaging signals from 150 laser shots. The uses of human specimen involved in this study were approved by the local Institutional Review Board and the samples were de-identified via random coding systems to protect human subject confidentiality.
Protein Peaks Identification
Three mice were sacrificed by CO 2 inhalation and crypts were isolated from the colons using the technique described previously (22) . Frozen adenoma was obtained from the remnant Apc Min+/-polyps after the LCM. The isolated colonic crypt pellet, frozen Apc Min+/-adenoma and a frozen human colorectal tumor were homogenized separately and fractionated using a reverse-phase HPLC as previously described (23) . The HPLC fractions containing the proteins with the target molecular weight were found using MALDI MS and digested using trypsin. The tryptic peptides were sequenced using reverse-phase capillary LC-MS/MS with LCQ Deca (ThermoFinnigan, San Jose, CA) as previously described (10) .
Database Searching
For analysis of the LCQ data, the RAW data files were converted to XML (Xtensible Markup Language) files using ReAdW (v. 3.5.1). Peptide assignment and protein identification were conducted using an on-line musculus database, and 17,759 entries for human databases). The mass spectra data was searched using a precursor ion mass error of +3.0 and -0.5 Da and a fragment mass error of 0.4 Da. Errors in assignment of monoisotopic mass were not permitted. Cysteine carbamidomethylation was a constant modification, and no other modifications, refinements, point mutations or missed cleavage were allowed. The threshold used for the building the model was log(e) < -1 for both peptide and proteins. The detailed descriptions for the MS/MS search parameters are described in the Supplementary Table 1 .
Immunohistochemistry
The S100a8 antibody was purchased from Accurate Chemical & Scientific Corporation (Westbury, NY). The Crip1 antibody was a kind gift from Dr. Robert Cousins. Formalin-fixed, paraffin-embedded tissue sections were prepared at 5μm thickness. The sections were first incubated in 0.03% hydrogen peroxide with sodium azide for 5 minutes, followed with incubation in Dako serum-free protein block reagent (Carpinteria, CA) for 15 minute. Dilutions of 1:200 (S100a8) and 1:50 (Crip1) were made for the primary antibody and the incubation time was 30 minutes (S100a8) and 120 minutes (Crip1) at room temperature. Then Dako Envision and HRP-labeled polymer were used for the secondary detection and the incubation time was 15 minutes. The sections were incubated in Dako DAB+ Chromogen for 3 minutes. Slides were dehydrated and coverslipped.
The S100a8 IHC staining intensity (0-3) and percentage (0-100%) were scored by a board certified pathologist who specializes in gastrointestinal cancer.
Gene Microarray Analysis
Total RNA from excised human CRC specimens was extracted and hybridizations were performed following the recommendations of the Affymetrix GeneChip U133 Plus 2.0 arrays were used. Scanned output files were visually inspected for hybridization artifacts. Gene expression was calculated using the MAS 5.0 algorithm and the data were scaled to a mean value of 500 for each chip. RNA expression levels of S100a8 in the different stages of CRC patients were compared.
Statistical Analysis
Statistically significant protein peaks were selected based on the significance analysis of microarrays, the Wilcoxon test, and the permutation t-test. The cutoff points for each method were 4, p<0.001, and p<0.001, respectively. The p-values were adjusted using the Benjamini-Hochberg False Discovery Rate control algorithm for multiple comparison analyses (25) . Protein markers that passed at least two of these three selection criteria were finally selected. The Weighted Flexible Compound Covariate Method (WFCCM) (26) was employed in the class-prediction model based on the selected proteins, to verify whether the proteomic patterns could be used to classify tissue samples into different groups. The WFCCM method reduced the dimensionality of the problem by using a new covariate obtained as a weighted sum of the most important predictors and combining the most significant proteins associated with the biological status from each analysis method. We estimated the misclassification rate using the leave-one-out cross-validation class prediction method based on the WFCCM results. Furthermore, the agglomerative hierarchical clustering algorithm was applied to investigate the classifications using the statistically significant discriminator protein peaks with Eisen's software (27) . To compare the overall proteomic profiles similarity between the adenomas vs. top and bottom crypts, multidimensional scaling (MDS) analysis (28) was performed. MDS displays the structure of distance-like data as a geometric picture. MDS illustrates the structure of a set of study samples from data that approximate the distances between pairs of the study samples. Two similar study samples are represented by two points that are close together, and two dissimilar study samples are represented by two points that are far apart. The result of MDS is usually a three-dimensional Euclidean space. In addition, the Euclidean distance-based general linear model was applied to test the similarity among the three study groups. 
Results
Protein Profiles from the Crypt Top, Crypt Bottom, and Apc
Proteomic Pattern Classifications and Comparisons among the Crypt Tops, Crypt Bottoms, and Adenomas
To detect the proteins that were differentially expressed among the crypt tops, crypt bottoms, and adenomas, multiple statistical analyses were performed with the data. Using the significant biomarkers identified by these statistical analyses, the protein profiles from the three different groups were compared. The classification accuracies assessed using leave-one-out cross-validation are shown in Table 1 . The top thirds and bottoms thirds of crypts were distinguished from each other with 71% accuracy based on 14 differentially expressed protein peaks. For the comparisons of the adenomas, 99% and 100% classification accuracies were achieved, for both the top and bottom crypt compartments vs. adenomas, using 68 and 43 differentially expressed protein peaks, respectively.
An agglomerative hierarchical clustering algorithm(30) was applied to further evaluate and visualize the different classifications using the protein markers selected by the WFCCM analysis. For the comparison of crypt tops and bottoms, 127 out of 139 protein profiles were correctly clustered into two groups ( Figure 3A ).
For the comparison of crypt tops and adenomas, they were clustered into two different groups with 100% accuracy ( Figure 3B ). Similarly, 65 crypt bottom protein profiles were clustered separately from the 86 adenoma protein profiles ( Figure 3C ). The Apc Min+/-adenoma protein profiles obtained from the small and large intestines did not segregate to distinct groups. Furthermore, we compared the similarity of the protein profiles obtained from the crypt tops and crypt bottoms with the adenomas using multidimensional scaling analysis ( Figure 3D ). The overall proteomic pattern similarities were found to be closer between the crypt bottoms with adenomas than the crypt tops with adenomas (P < 0.001).
Identification and Validation of Protein Markers
Proteins that were differentially expressed between normal crypts and adenomas were identified using tandem mass spectrometry. For each of these identified proteins, at least two corresponding peptides were confirmed from the MS/MS spectra. These identified proteins were serine protease inhibitor kazal type 3 (Spink3), calmodulin (Calm1), cysteine-rich intestinal protein (Crip1), calgranulin A (S100a8), and galectin-2 (Lgals2). Spink3, Crip1, and Calm1 were overexpressed in the normal crypts when compared to the adenomas. Specifically, Spink3 and Crip1 were more highly expressed in the crypt top compared to crypt bottom. S100a8 and Lgals2 were found overexpressed in the adenomas. In addition, the protein peak corresponding to macrophage migration inhibitory factor (Mif)(31) was also found overexpressed in the adenomas. The average molecular weight, Swiss-Prot accession number, number of peptides identified, overexpressed region and brief descriptions of the biological functions of these proteins are shown in Table 2 .
The complete annotations for the protein identification and all of the corresponding MS/MS spectra are listed in the Supplementary Table 2 .
To validate the differentially expressed proteins, Crip1 was further analyzed for its differential expression in the crypt top, crypt bottom and Apc Min+/-adenomas. Immunohistochemistry was performed to examine the expression of Crip1 in normal mouse crypt and Apc Min+/-adenomas. As shown in Figure 4A , using LCM combined with MALDI MS, Crip1 was more highly expressed in the crypt top, compared with crypt bottom or Apc Min+/-adenomas, which is consistent with the findings from IHC ( Figure 4B and 4C).
Identification and Confirmation of S100a8 in Human Colorectal Cancer
To demonstrate the relevance of the identified protein biomarkers in human CRC, S100a8 was chosen as an example and was further identified in human CRC specimen. The theoretical molecular weight of human S100a8 is 10,835 Da. Protein profiles from human adjacent normal colonic mucosa and CRC were obtained.
The protein peaks corresponding to S100a8 were higher in the CRC compared with normal colonic crypts, as shown in figure 5 (A, B) . To verify its identification, this human CRC tissue was homogenized and fractionated by HPLC. The HPLC fraction which contained a protein peak with m/z (mass to charge ratio) value of 10,836
Da was obtained. After digestion of this HPLC fraction with trypsin, the peptides were analyzed using tandem mass spectrometry. Five peptides from S100a8 were found, comprising a total of 51% of the total amino acid sequence. All of the MS/MS spectra corresponding to the human S100a8 are shown in Supplementary Table   2 . To further confirm the identification, S100a8 expression was assessed by immunohistochemistry in the same human CRC case. The staining of S100a8 in histologically invasive colon carcinoma ( Figure 5C ) and normal colonic mucosa ( Figure 5D ) are shown. For IHC, the tumor shows strong diffuse cytoplasmic and nuclear staining, and is increased as compared to the normal crypts. The normal crypts show patchy nuclear staining in crypt epithelium, but that is not present in every cell. The stroma staining is similar to tumor stroma.
The lamina propria and inflammatory cells exhibit positive staining. The IHC results for S100a8 from nine human CRC with adjacent normal crypts are shown in Figure 5E . The corresponding MALDI mass spectra obtained from some of these cases were shown in Figure 5F . Overall, S100a8 was found to be expressed significantly higher in CRC compared to normal crypts using both IHC (p < 0.02) and MALDI MS (p < 0.001).
S100a8 Differential Expression in Human CRC
To further analyze the differential expression of S100a8 at the protein level in human CRC, we examined its expression in a cohort of samples comprised of 66 human normal controls and 104 CRC cases representing Duke's stages A-D. The protein profiles were obtained from normal colonic crypts and CRC tumor cells using MALDI MS. The protein peak corresponding to S100a8 was compared among the control cases and the four progressive stages of CRC. S100a8 expression within CRC stages A-D was increased compared to normal controls (p < 0.001) ( Figure 6A ). Furthermore, S100a8 expression at the mRNA level was also evaluated in an independent cohort of patients using the Affymetrix GeneChip. The expression levels of S100a8 among normal and colorectal adenocarcinoma, Duke's Stage A-D, are shown in Figure 6B . An increased expression trend was observed from normal to stage A, B, and C. When compared to normal controls, statistically significant changes in S100a8 expression were observed in Duke's stage B, C, and D (p <0.05). Overall, the proteomic finding of increased S100a8 expression in the Apc Min+/-adenomas, combined with the proteomic and microarray findings from human colorectal cancer, suggest that S100a8 is upregulated during the progression of human CRC.
Discussion
In this study, we first compared the protein profiles among the upper one-third of colonic crypts and the bottom third of these crypts, as well as Apc Min+/-adenomas, using LCM and MALDI MS. Different proteomic patterns were obtained and compared. Both previously known and novel protein biomarkers were identified.
One of the protein biomarkers was further identified in human CRC and its differential expression was shown at the RNA and protein expression levels in human CRC cases.
The proliferative and progenitor compartment in the base of the colonic crypt is predicted to have a different protein expression profile as compared to the post-replicative, differentiated compartment in the upper portion of crypt. According to the "bottom up" theory, the daughter cells rapidly proliferate and migrate up along the crypt, where they undergo apoptosis and are shed into the lumen (32) . Genetic mutations in daughter cells are lost as they consistently shed out of the crypt. However, stem cells, which until recently could not be identified morphologically or reliably distinguished using molecular markers (33) , reside in a niche near the bottom of the crypt. Oncogenic mutations are thought to accumulate in the base of the crypt compartment, which make stem cells the suspected target cell of origin for colonic neoplasia (34) . In the present study, the protein profiles from the Apc Min+/-adenomas are more similar to the protein profiles obtained from the base of crypts than from the top colonic epithelium, which is consistent with the "bottom up" theory at the molecular level. This is consistent with previous observations which suggested that early adenomas represented an expansion of the colonic crypt base cell population (13) .
Some factors that may cause overestimation of the prediction accuracy of the proteomic pattern classification should be addressed. First, because the same samples were used to both select and test marker proteins, overestimation of prediction accuracy is possible in our study. The ideal situation for highdimensional biomarker research is to include not only a training dataset but also an independent test dataset.
The results from the training dataset should then be confirmed by the test dataset to avoid overfitting in the classifier selection. In addition, to build a reliable statistical prediction model, the training dataset should be reasonably large. Second, supervised hierarchical clustering analysis uses covariates specifically chosen for maximal discriminating power. The excellent result from the hierarchical clustering is expected because the covariates used in the analysis were significantly different between study groups (35) . Finally, the number of peaks selected is not based on the smallest number of features that could discriminate the classes but is based on the statistical evidence; therefore, different subsets of protein peaks may achieve similar misclassification rates (36) .
Besides the obvious differences between mouse and human, most of the transgenic models for cancer are created by manipulating one or two genes, while human tumors are known to have multiple gene mutations throughout cancer development (37) . For human cancer biomarker discovery, it would be ideal to study human specimens directly. However, transgenic mouse model is excellent for technology assessment of direct protein profiling using LCM combined with MALDI MS. Furthermore, the mouse colon adenoma protein biomarkers identified in our findings are shown to be relevant in human CRC specimens. For example, the cytokine macrophage migration inhibitory factor (MIF) was identified as a protein biomarker overexpressed in adenoma, when compared with normal crypts. Similarly, MIF has been shown to be overexpressed in human CRC (38) . The number and size of Apc Min+/-mouse adenomas were significantly reduced with the homozygous deletion of MIF (39) . It has been suggested that MIF could promote colon cancer invasion and metastasis via the Rho-dependent pathway (40, 41) . Anti-MIF antibody has also been shown to suppress tumor growth in vivo and inhibits tumor-associated angiogenesis (42) . S100a8 was another biomarker identified in the Apc Min+/-mouse adenomas, and we further confirmed that its expression increases as human CRC progresses from normal to higher stages (Duke's stages A-D), at both protein and RNA levels, in two relatively large human CRC sample sets. S100a8 binds with calgranulin B to form a complex called calprotectin (43) . As a calcium and zinc binding protein, calprotectin is a multipotent molecule and can inhibit several zinc-dependent metalloproteinases by sequestration of zinc (44) . S100a8 and S100a9 have been shown to increase tumor cells invasion activity with pseudopodia through activation of the mitogen-activated protein kinase (MAPK) p38 (45) . S100a8 has also been reported previously to be overexpressed in other types of cancers, including oral, breast, and prostate cancers (46) (47) (48) .
In addition, novel proteins that were found to be differentially expressed in normal crypts and intestinal neoplasia were identified in our study. Lgals2 was found to be overexpressed in the Apc Min+/-adenomas as compared to normal colonic crypts. Lgals2 belongs to the galectin family which binds specifically to β-galactose-containing oligosaccharides (49) . Although Lgals2 has not been previously reported as overexpressed in intestinal neoplasia, galectin-1 and galectin-3, two other proteins in the galectin family, have been shown to be upregulated in human colon cancer (50) , pancreatic cancer (51), and head and neck squamous cell carcinoma (52) . Increased galectin-3 expression correlates with decreased survival in patients with colorectal cancer (53) . The proteins found decreased in adenomatous cells included Crip1, Spink3 and
calmodulin. The precise roles of these proteins in CRC tumorigenesis and development also need further investigation. Crip1 contains a double zinc finger motif and is a member of the LIM protein family (54) . Crip1
has been suggested to play a role in host defense system, and differential expression of Crip1 can change cytokine patterns and immune response (55) . Mutational loss of Spink3 function is associated with enhanced trypsin activity and pancreatitis (56, 57) . The overexpression of Spink3 in the crypt top, as found in our study, suggest a role in the protection of colon mucosa against trypsin activity. Calmodulin is one of the major cellular Ca 2+ binding proteins and is important in cellular regulation (58, 59) . Death-associated protein kinase (DAPK), a calmodulin-dependent serine/threonine kinase, is a positive mediator of apoptosis (60) . Loss of DAPK activity leads to protection from IFN-γ-induced cell death and overexpression of DAPK leads to apoptosis (61) . The inactivation of DAPK by promoter hypermethylation has also been suggested to play an important role in the early steps of tumor progression to colorectal carcinoma (62) . Thus, down regulation of calmodulin may contribute to colorectal tumorigenesis via inactivation of DAPK.
In conclusion, LCM combined with MALDI MS is a robust method for protein biomarker discovery using minute amounts of samples. Identification of novel intestinal protein biomarkers from the top and bottom crypts will increase our knowledge of the protein changes taking place during cells migration from the crypt bottom to the top. Furthermore, the cancer protein biomarkers identified from the Apc Min+/-mouse model were validated in human CRC specimens. These cancer protein biomarkers will aid in the exploration of colorectal tumorigenesis mechanisms as well as in the advancement of molecular-based diagnosis of colorectal cancer. select the statistically significant peaks that allowed the classification of the three groups of samples. The classification accuracies were calculated using the leave-one-out cross-validation classification methods 
